The ink is barely dry on the framework memorandum of understanding signed between the United States and Iran in June 2026 and already strategic planners in the pharmaceutical and healthcare industries are looking east to a country of 88.6 million people whose medical market has been artificially compressed for decades. The deal, which established a 60-day ceasefire, outlined the phased reopening of the Strait of Hormuz and put sanctions relief firmly on the negotiating table, marks a potential inflection point for one of the Middle East's most underserved and most overlooked healthcare economies.
The opportunity, however, is not simple. It is layered, contingent and demands a clear-eyed understanding of what Iran's healthcare landscape actually looks like in 2026.
A Market Shaped by Siege
To understand where Iran's pharma sector is going, you must first appreciate where decades of isolation brought it. Under sustained US-led sanctions, Iran was effectively cut off from the global pharmaceutical supply chain- not because medicines were ever formally banned, but because financial restrictions, currency collapses and the fear of secondary penalties made doing business with Iranian entities nearly impossible for multinational companies.
The consequences were severe. Sanctions led to a one-third decrease in public purchasing power for healthcare, triggered shortages of 73 essential medications- 44% of which are classified as essential by the WHO and limited access to treatment for an estimated 6 million patients. Medicine prices surged by as much as 50% as import channels dried up.
And yet, Iran's pharmaceutical industry didn't collapse. It transformed.
Driven by necessity, Iran turned inward. The country now produces approximately 95–97% of its own medicines domestically, supported by over 180 licensed manufacturers. It established a solid biosimilar segment, including for example Cinnagen, Sobhan Pharmaceutical and Exir Pharmaceutical that became successful producers of insulin, EPO and other biological medicines that, without the local alternative, would need to be imported. The job of producing these was undertaken by Iranian Universities and faculties of Pharmacy, together with knowledge-based companies who formed an ecosystem of innovation under duress.
Today, Iran is the second-largest pharmaceutical market in the MENA region by volume, valued at approximately $4.2 billion and growing at 7.3% year-over-year. Projections place the market at nearly $9.7 billion by 2029.
What the Deal Actually Unlocks
The June 2026 framework is not a final peace settlement- it is a structured pause with economic incentives attached. Critically, it includes discussions over sanctions relief and the possible release of up to $25 billion in frozen Iranian assets, conditional on compliance during the 60-day negotiation window.
For the healthcare and pharma sector, even partial sanctions easing could unlock several immediate dynamics:
- Re-entry of International Supply Chains: The single biggest bottleneck for Iran's pharmaceutical industry has never been domestic manufacturing capacity but it has been the import of active pharmaceutical ingredients (APIs) and stabilizing compounds, mostly sourced from China and India. Even with near-total domestic drug production, global-standard APIs require hard-currency payment channels that sanctions made nearly impossible. Restoring those channels would reduce production costs and end chronic API shortages that threatened to shut down entire drug categories.
- Multinational Re-engagement: Companies like Novartis, Roche and Sanofi have historically operated in Iran only through local distributors, severely constrained by compliance risk. A sanctions relief pathway opens the door for formal re-entry: licensing agreements, joint ventures, technology transfer deals and eventually direct market presence. For multinationals seeking to diversify beyond saturated Western markets, Iran's combination of a large, educated population, rising chronic disease burde, and suppressed import penetration is compelling.
- Oncology, Monoclonal Antibodies, and SpecialtyBiologics: Iran has advanced health infrastructure, substantial numbers of specialty physicians, tertiary hospitals and an oncology patient population that has had extremely limited access to cutting-edge therapies. Cancer patients across the country have been forced off treatment due to unaffordable or unavailable novel drugs. Post-deal, monoclonal antibodies and recombinant protein therapies represent the highest-value, most immediate commercial opportunity for international pharma.
- 4. Medical Devices & Diagnostics: Iran’s hospitals are desperately in need of an upgrade. Their manufacturing facilities for medications have been around more than 50 years on average. Imaging systems, surgical equipment, medical diagnostic systems and even the infrastructure for digital health is another opportunity area for medical technologies (MedTech). Medical product registrations with Iran’s Food & Drug Administration (IFDA) usually takes 12-24 months and an early start is beneficial to any companies looking to take advantage of market opening.
- Iran as a Regional Export Hub: Before dismissing Iran as merely a destination market, consider its potential as an origin. Iran already exports medicines to Iraq, Afghanistan and several CIS countries. With modern GMP upgrades, technology transfer from international partners and restored banking channels, Iranian manufacturers could become competitive exporters across a belt of under-pharmed neighbors, creating a value chain proposition for foreign investors, not just a sales opportunity.
The Risks Are Real
No honest assessment of this market can ignore the obstacles.
The deal remains fragile. Key issues including the final status of Iran's nuclear enrichment program remain unresolved and the 60-day framework is explicitly a temporary stabilization measure. Compliance, verification and the outcome of follow-on talks will determine whether sanctions relief materializes meaningfully or stalls.
Regulatory complexity is genuine. IFDA dossier submissions require Persian-language labelling, full GMP certification and stability data- a 12 to 24 month pathway under the best conditions. Banking and payment infrastructure, long atrophied by isolation, will need to be rebuilt before routine transactions are feasible.
Pricing dynamics also require care. Iran's pharmaceutical market is highly regulated, with a structured copayment model in which individuals pay 20%, insurance funds cover 45% and government subsidizes 35% of the lowest-cost generics. Premium pricing strategies common in Western markets will not translate without structural negotiation.
And there is the persistent geopolitical overhang: Israel and several Gulf states have already expressed concerns about the deal's unresolved provisions. Secondary sanctions risk, though diminished, has not disappeared.
The Strategic Window
History suggests that pharmaceutical companies that move early in post-sanctions markets establishing regulatory filings, building local partnerships, and embedding distribution relationships gain durable first-mover advantages. The 2016 JCPOA relief period was brief, but the companies that moved swiftly learned the landscape and built relationships that outlasted the policy reversal.
This window may be wider or it may close again. But the underlying market reality is unchanged: Iran is a country of nearly 90 million people with a sophisticated but supply-starved healthcare system, a rapidly aging population, a growing chronic disease burden and decades of pent-up demand for medicines its own doctors cannot currently prescribe.
The US-Iran deal has not solved all the problems. But it has opened the door.
For pharma and healthcare companies willing to do the regulatory groundwork now, the question is not whether Iran is a market worth entering. The question is whether they can afford to be last.